BIIB vs TU Comparison

Biogen is an established biopharmaceutical company focused on treatments for neurodegenerative and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 40% of total revenue in 2025. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (19% of total in 2025), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).

Telus is one of Canada's Big Three telecom service providers, offering wireless and broadband services nationally, but with strongholds in British Columbia and Alberta. The firm serves 10 million postpaid and prepaid wireless customers. It counts nearly 3 million broadband customers across a network footprint that passes more than 4 million homes. The firm operates two additional segments, Telus Health and Telus Digital. Telus Health covers 170 million individuals, offering preventive medicine and virtual care in 200 countries. Telus Digital primarily offers third-party customer support, online content moderation, and data transformation.